{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T19:50:33Z","timestamp":1712173833860},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00292-022-01052-w","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T07:02:39Z","timestamp":1644994959000},"page":"157-166","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histopathologische Evaluierung der nichtalkoholischen Fettleber"],"prefix":"10.1007","volume":"43","author":[{"given":"Nada","family":"Abedin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Tischoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"1052_CR1","doi-asserted-by":"publisher","first-page":"18454","DOI":"10.1038\/s41598-019-54904-6","volume":"9","author":"F Heinemann","year":"2019","unstructured":"Heinemann\u00a0F, Birk\u00a0G, Stierstorfer\u00a0B (2019) Deep learning enables pathologist-like scoring of NASH models. Sci Rep 9:18454","journal-title":"Sci Rep"},{"issue":"4","key":"1052_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41416-020-01122-x","volume":"124","author":"A Echle","year":"2021","unstructured":"Echle\u00a0A, Rindtorff\u00a0NT, Brinker\u00a0TJ, Luedde\u00a0T, Pearson\u00a0AT, Kather\u00a0JN (2021) Deep learning in cancer pathology: a\u00a0new generation of clinical biomarkers. Br J Cancer 124(4):686\u2013696","journal-title":"Br J Cancer"},{"issue":"1","key":"1052_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30535-1","volume":"8","author":"E Arvaniti","year":"2018","unstructured":"Arvaniti\u00a0E, Fricker\u00a0KS, Moret\u00a0M, Rupp\u00a0N, Hermanns\u00a0T, Fankhauser\u00a0C, Wey\u00a0N, Wild\u00a0PJ, Claassen\u00a0M (2018) Automated Gleason grading of prostate cancer tissue microarrays via deep learning. Sci Rep 8(1):1\u201311","journal-title":"Sci Rep"},{"key":"1052_CR4","first-page":"199","volume":"118","author":"S F\u00f6rsch","year":"2021","unstructured":"F\u00f6rsch\u00a0S, Klauschen\u00a0F, Hufnagl\u00a0P, Roth\u00a0W (2021) K\u00fcnstliche Intelligenz in der Pathologie. Dtsch Arztebl Int 118:199\u2013204","journal-title":"Dtsch Arztebl Int"},{"key":"1052_CR5","doi-asserted-by":"publisher","first-page":"106153","DOI":"10.1016\/j.cmpb.2021.106153","volume":"207","author":"Q Hui","year":"2021","unstructured":"Hui\u00a0Q, Minacapelli\u00a0CD, Tait\u00a0C, Gupta\u00a0K, Bhurwal\u00a0A, Catalano\u00a0C, Dafalla\u00a0R, Metaxas\u00a0D, Rustgi\u00a0V (2021) Training of computational algorithms to predict NAFLD activity score and fibrosis stage from liver hepatology slides. Comput Methods Programs Biomed 207:106153","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1052_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hep.31750","volume":"74","author":"A Taylor-Weiner","year":"2021","unstructured":"Taylor-Weiner\u00a0A, Pokkalla\u00a0H, Han\u00a0L, Jia\u00a0C, Huss\u00a0R, Chung\u00a0C, Younossi\u00a0ZM (2021) A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology 74(1):133\u2013147. https:\/\/doi.org\/10.1002\/hep.31750","journal-title":"Hepatology"},{"key":"1052_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1055\/s-0035-1553193","volume":"53","author":"E Roeb","year":"2015","unstructured":"Roeb\u00a0E, Steffen\u00a0HM, Bantel\u00a0H, Baumann\u00a0U, Canbay\u00a0A, Demir\u00a0M, Drebber\u00a0U, Geier\u00a0A, Hampe\u00a0J, Hellerbrand\u00a0C, Pathil-Warth\u00a0A, Schattenberg\u00a0JM, Schramm\u00a0C, Seitz\u00a0HK, Stefan\u00a0N, Tacke\u00a0F, Tannapfel\u00a0A, Lynen Jansen\u00a0P, Bojunga\u00a0J (2015) S2K Guideline non-alcoholic fatty liver disease. Z\u00a0Gastroenterol 53:668\u2013723","journal-title":"Z Gastroenterol"},{"issue":"12","key":"1052_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka\u00a0AC, Adeyi\u00a0O, Thompson\u00a0J, Hameed\u00a0B, Crawford\u00a0PA, Ikramuddin\u00a0S (2020) Nonalcoholic steatohepatitis: a\u00a0review. JAMA 323(12):1175\u20131183","journal-title":"JAMA"},{"key":"1052_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa\u00a0P, Poitou\u00a0Ch, Veyrie\u00a0N, Bouillot\u00a0JL, Basdevant\u00a0A, Paradis\u00a0V, Tordjman\u00a0J, Clement\u00a0K (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751\u20131759","journal-title":"Hepatology"},{"key":"1052_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa\u00a0P, FLIP Pathology Consortium (2014) Utiliy and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60:565\u2013575","journal-title":"Hepatology"},{"key":"1052_CR11","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor\u00a0RS, Taylor\u00a0RJ, Bayliss\u00a0S, Hagstr\u00f6m\u00a0H, Nasr\u00a0P, Schattenberg\u00a0JM, Ishigami\u00a0M, Toyoda\u00a0H, Wong\u00a0VWS, Peleg\u00a0N, Shlomai\u00a0A, Sebastini\u00a0G, Seko\u00a0Y, Bhala\u00a0N, Younossi\u00a0ZM, Anstee\u00a0QM, McPherson\u00a0S, Newsome\u00a0PN (2020) Association between fibrosis stage and outcome of patients with nonalcoholic fatty liver disease: a\u00a0systematic review and meta-analysis. Gastroenterology 158:1611\u20131625","journal-title":"Gastroenterology"},{"key":"1052_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/liv.13653","volume":"38","author":"P Bedossa","year":"2017","unstructured":"Bedossa\u00a0P (2017) Diagnosis of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis. Why liver biopsy is essential? Liver Int 38:64\u201366","journal-title":"Liver Int"},{"key":"1052_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt\u00a0EM, Kleiner\u00a0DE, Wilson\u00a0LA, Belt\u00a0P, Neuschwander-Tetri\u00a0BA, NASH clinical research network (CRN) (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathological diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810\u2013820","journal-title":"Hepatology"},{"key":"1052_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner\u00a0DE, Brunt\u00a0EM, Van Natta\u00a0M, Behling\u00a0C, Contos\u00a0MJ, Cummings\u00a0OW, Ferrell\u00a0LD, Liu\u00a0YCH, Torbenson\u00a0MS, Unalp-Arida\u00a0A, Yeh\u00a0M, McCullough\u00a0AJ, Sanyal\u00a0AJ, NASH clinical research network (CRN) (2005) Design and validation of histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321","journal-title":"Hepatology"},{"key":"1052_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-011-1066-1","volume":"458","author":"A Tannapfel","year":"2011","unstructured":"Tannapfel\u00a0A, Denk\u00a0H, Dienes\u00a0HP, Dienes\u00a0HP, Langner\u00a0C, Schirmacher\u00a0P, Trauner\u00a0M, Flott-Rahmel\u00a0B (2011) Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 458:511\u2013523","journal-title":"Virchows Arch"},{"issue":"4","key":"1052_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17474124.2018.1415756","volume":"12","author":"F Nascimbeni","year":"2018","unstructured":"Nascimbeni\u00a0F, Ballestri\u00a0S, Machado\u00a0MV, Mantovani\u00a0A, Cortez-Pinto\u00a0H, Targher\u00a0G, Lonardo\u00a0A (2018) Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev Gastroenterol Hepatol 12(4):351\u2013367","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"36","key":"1052_CR17","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","volume":"23","author":"A Lonardo","year":"2017","unstructured":"Lonardo\u00a0A, Nascimbeni\u00a0F, Maurantonio\u00a0M, Marrazzo\u00a0A, Rinaldi\u00a0L, Adinolfi\u00a0LE (2017) Nonalcoholic fatty liver disease: evolving paradigms. World J Gastroenterol 23(36):6571","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1052_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/gutjnl-2020-322880","volume":"70","author":"J Calderaro","year":"2021","unstructured":"Calderaro\u00a0J, Kather\u00a0JN (2021) Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers. Gut 70(6):1183\u20131193","journal-title":"Gut"},{"key":"1052_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.02.011","author":"A Stenzinger","year":"2021","unstructured":"Stenzinger\u00a0A, Alber\u00a0M, Allg\u00e4uer\u00a0M, Jurmeister\u00a0P, Bockmayr\u00a0M, Budczies\u00a0J, Lennerz\u00a0J, Eschrich\u00a0J, Kazdal\u00a0D, Schirmacher\u00a0P, Wagner\u00a0AH (2021) Artificial intelligence and pathology: from principles to practice and future applications in histomorphology and molecular profiling. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2021.02.011","journal-title":"Semin Cancer Biol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01052-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-022-01052-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01052-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:04:54Z","timestamp":1646121894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-022-01052-w"}},"subtitle":["Automatisierte Auswertung von Leberstanzen"],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s00292-022-01052-w","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"29 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>N.\u00a0Abedin<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: F\u00f6rderung durch das Patenschaftsmodell der Frankfurter Forschungsf\u00f6rderung des Fachbereichs Medizin der Goethe Universit\u00e4t Frankfurt.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Medizinische Klinik\u00a01, Klinik f\u00fcr Gastroenterologie und Hepatologie, Universit\u00e4tsklinikum Frankfurt, Goethe Universit\u00e4t | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), American Association for the Study of Liver Diseases (AASLD), American Society of Clinical Oncology (ASCO).<b>A.\u00a0Tannapfel<\/b>: A.\u00a0Finanzielle Interessen: A.\u00a0Tannapfel gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktorin, Institut f\u00fcr Pathologie der RUB, Dekanin der Medizinischen Fakult\u00e4t der RUB ab 01.10.2021, Bochum | Mitgliedschaft: Deutsche Krebsgesellschaft (Sprecherin Sektion\u00a0B, Stellvertreterin des Pr\u00e4sidenten).<b>P.J.\u00a0Wild<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung: AstraZeneca.\u00a0\u2013 Honorare f\u00fcr Vortr\u00e4ge: Bayer, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers-Squibb, Thermo Fisher Scientific, Molecular Health, Sophia Genetics, Qiagen, Eli Lilly, Myriad Genetics und AstraZeneca, Hedera DX.\u00a0\u2013 Aktien: BioNTech.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Mitglied DGP, BDP, ESP, AACR | Direktor Dr. Senckenbergisches Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt am Main | Senior Fellow Frankfurt Institute for Advanced Studies (FIAS), Frankfurt am Main | Angestellter Facharzt Wildlab UKF MVZ GmbH, Frankfurt am Main.<b>I.\u00a0Tischoff<\/b>: A.\u00a0Finanzielle Interessen: I.\u00a0Tischoff gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Pathologin, Institut f\u00fcr Pathologie, Ruhr-Universit\u00e4t Bochum | Mitgliedschaft: Internationale Akademie f\u00fcr Pathologie (IAP).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}